Pipeline Moves: Investigator-led trial of Lilly's merestinib in solid tumours terminated [Yahoo! Finance]
Leap Therapeutics Announces $40 Million Private Placement [Yahoo! Finance]
Leap Therapeutics Announces $40 Million Private Placement
Leap Therapeutics, Inc. (NASDAQ: LPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Leap Therapeutics, Inc. (NASDAQ: LPTX) had its price target lowered by analysts at Robert W. Baird from $11.00 to $9.00. They now have an "outperform" rating on the stock.